scholarly article | Q13442814 |
P50 | author | Connie Celum | Q42571941 |
Guido Ferrari | Q56481169 | ||
David C. Montefiori | Q63302725 | ||
Nina D. Russell | Q109927619 | ||
Elizabeth Noonan | Q109934089 | ||
Kent J. Weinhold | Q109935303 | ||
P2093 | author name string | J M Smith | |
M J Mulligan | |||
J Kahn | |||
H L Robinson | |||
R R Amara | |||
NIH/NIAID/DAIDS HIV Vaccine Trials Network | |||
P433 | issue | 7 | |
P921 | main subject | vaccine | Q134808 |
vector-borne disease | Q2083837 | ||
P304 | page(s) | 678-683 | |
P577 | publication date | 2006-07-01 | |
P1433 | published in | AIDS Research and Human Retroviruses | Q4651880 |
P1476 | title | Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults | |
P478 | volume | 22 |
Q46171221 | Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses |
Q55432126 | Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design. |
Q33614476 | Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine |
Q42410705 | Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques |
Q37329415 | Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. |
Q36528901 | Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers |
Q42554027 | Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers |
Q37103923 | Current progress of DNA vaccine studies in humans |
Q34492802 | DNA/MVA Vaccines for HIV/AIDS |
Q35857215 | Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors |
Q28972526 | Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial |
Q36498186 | Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". |
Q45031334 | Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation |
Q38877415 | Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans |
Q37773283 | Maternal immunization to modulate the development of allergic response and pathogen infections. |
Q36748019 | Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration |
Q33645528 | Novel directions in HIV-1 vaccines revealed from clinical trials |
Q38586079 | Nucleic acid vaccination strategies against infectious diseases. |
Q30378897 | Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. |
Q33527383 | Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine |
Q34772727 | Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles |
Q30379200 | Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). |
Q39862726 | Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge |
Q91890041 | Rectal Microbiome Composition Correlates with Humoral Immunity to HIV-1 in Vaccinated Rhesus Macaques |
Q36668517 | Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults. |
Q45398885 | Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults |
Q27016078 | Synthetic DNA vaccine strategies against persistent viral infections |
Q24602593 | Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients |
Search more.